Evidence map›Paper›PMID 38715128›Full record

ArticleBMC chemistry2024

Synthesis and antitumor activity of dolutegravir derivatives bearing 1,2,3-triazole moieties.

Xixi Hou, Longfei Mao, Yajie Guo, Lan Wang, Lizeng Peng, Huili Wang, Jianxue Yang, Sanqiang Li, Yue-Ming Li

Abstract read
In one paragraph

Article in BMC chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. 2Frontiers in pharmacology · 2025
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xixi Hou *Department of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China.
Longfei Mao *College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, 263 Kaiyuan Road, Luoyang, 471003, China. longfeimao1988@163.com.
Yajie Guo *Department of Emergency, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, 518033, China.
Lan WangCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, 263 Kaiyuan Road, Luoyang, 471003, China.
Lizeng PengInstitute of Agro-Food Science and Technology, Key Laboratory of Agro-Products Processing Technology of Shandong Province, Key Laboratory of Novel Food Resources Processing Ministry of Agriculture, Shandong Academy of Agricultural Sciences, Jinan, 250100, China.
Huili WangUniversity of North Carolina Hospitals, 101 Manning Dr, Chapel Hill, Orange County, NC, 27599, USA.
Jianxue YangDepartment of Pharmacy, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, Luoyang, 471003, China. Docyjx@126.com.
Sanqiang LiCollege of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, 263 Kaiyuan Road, Luoyang, 471003, China. sanqiangli2001@163.com.
Yue-Ming LiState Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin, 300350, China. ymli@nankai.edu.cn.

Funding

2023 Henan Province Central guidance and local science and technology development fund support project Z20231811030Basic Research Project of Key Scientific Research Projects of Universities in Henan Province 23ZX006International Science and Technology Cooperation Project of Henan Province of China 242102520016National Natural Science Foundation of China 82170606Shenzhen Science and Technology Program JCYJ20210324115208024
6 · The paper itself

Abstract

Modification of marketed drugs is an important way to develop drugs because its safety and clinical applicability. Oxygen-nitrogen heterocycles are a class of important active substances discovered in the process of new drug development. Dolutegravir, an HIV drug with a nitrogen-oxygen heterocycle structure, has the potential ability to inhibit cell survival. In order to find and explore novel anti-tumor drugs, new dolutegravir derivatives bearing different 1,2,3-triazole moieties were prepared via click reactions. In vitro biological experiments performed in several lung cancer cell lines suggested that these novel compounds displayed potent anti-tumor ability. Especially, the compound 9e with a substituent of 2-methyl-3-nitrophenyl and the compound 9p with a substituent of 3-trifluoromethylphenyl were effective against PC-9 cell line with IC

Indexed as

1, 2, 3-triazoleAntitumorAutophagyDolutegravirSynthesis

Identifiers

PMID38715128
PMCPMC11077815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.